Navigation Links
Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
Date:2/26/2008

REINACH, Switzerland, February 26 /PRNewswire-FirstCall/ -- Arpida Ltd. (SWX: ARPN) today reported that the rolling submission of the New Drug Application (NDA) for intravenous iclaprim in its first indication, complicated Skin and Skin Structure Infections (cSSSI) will be completed within the next few weeks.

Arpida has agreed with the U.S. Food and Drug Administration (FDA) to file the NDA in a rolling process. Using a 'rolling NDA' allows modules within the overall package to be filed individually. Arpida has further agreed to file the NDA in an electronic format. Both the rolling NDA and the electronic format could potentially facilitate the review process.

Dr Khalid Islam, President and CEO of Arpida Ltd., commented: "Completing the submission of the NDA as soon as possible, while at the same time maintaining high standards of quality, remains our highest priority. Unfortunately, some of the data to be included in the NDA package were delivered later than anticipated. These delays were amplified by the additional processing steps that need to be taken for the electronic format in which we are filing, such as the incorporation of hyperlinks between the different parts of this huge and complex data package. We have only limited reference data regarding such projects and we underestimated the magnitude of the additional processing steps. Our development team and our external partners have been doing their utmost to complete the project within the February timeline. Rushing through the final processing procedure could jeopardise the quality. We strongly believe that safeguarding a high quality level at this crucial stage of iclaprim's development process is in the best interest of our stakeholders in the longer term. Based on the current status of the project, we anticipate the filing to be completed within the next few weeks."

Conference Call

Arpida will host a conference call to discuss this news release, 27

February
'/>"/>

SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arpida Interim Results for six Months to 30 June 2007
2. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
3. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
4. Arpida Presents Preclinical Data on AR-2474 at ICAAC
5. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
6. Arpida-Supported CME Symposium Available Online
7. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
8. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
9. CardioDynamics Provides 2007 Shareholder Meeting Update
10. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
11. NxStage Medical Provides Update on Medisystems Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Pittcon Organizing Committee is pleased to ... Tech , an e-Journal and producer of Food ... second year for the co-location of Food Labs Conference to ... that the registration fee to attend the two-day Food Lab ...
(Date:1/15/2014)... , Jan. 15, 2014 ­ RedBrick Health ... behavior change technology, today announces that EmblemHealth , ... and wellness company, is now providing the RedBrick Compass ... coaching program, to all of its members. EmblemHealth is ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains ... these latent viruses is the Epstein Barr Virus (EBV), and ... (RA) is a chronic inflammatory disease that destroys the body’s ... RA patients have high concentrations of EBV DNA in their ...
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, Limited ... agreement with R-Pharm, a leading Russian pharmaceutical company, to ... Russian Federation , Turkey ... States (CIS). Nemonoxacin is a novel antibiotic for the treatment ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... Cell Therapeutics, Inc. ("CTI" or the "Company") (NASDAQ and MTA: ... first quarter of 2012. First Quarter ... expenses were $18.1 million compared to $20.1 million for the ... decreased 66% to $17.4 million ($0.09 per share) for the ...
... Mich., April 19, 2012  Researchers at Lund University in Sweden ... These cells can proliferate and form several different cell types ... hope to take advantage of the finding to develop methods ... Analyzing brain tissue from biopsies, the researchers for ...
... NAPERVILLE, Ill., April 19, 2012  Phigenics LLC, an innovative ... a research paper that demonstrates up to 33% false-positive ... conventional sampling methods. A false-positive result means the test ... system at detectable levels when in fact it was ...
Cached Biology Technology:Cell Therapeutics, Inc. (CTI) Reports First Quarter Financial Results and Milestones 2Cell Therapeutics, Inc. (CTI) Reports First Quarter Financial Results and Milestones 3Cell Therapeutics, Inc. (CTI) Reports First Quarter Financial Results and Milestones 4Cell Therapeutics, Inc. (CTI) Reports First Quarter Financial Results and Milestones 5New Stem Cell Found in the Brain 2New Stem Cell Found in the Brain 3Phigenics Research Challenges Accuracy Of Conventional Legionella Testing Protocol 2Phigenics Research Challenges Accuracy Of Conventional Legionella Testing Protocol 3
(Date:4/17/2014)... the immune system may fight cancers and viral infections. ... to treat illness. , The research, in mice, suggests ... police" specialized squads of defenders that patrol only ... city, the body. , Scientists at Washington University School ... liver, skin and uterus each has dedicated immune cells, ...
(Date:4/16/2014)... legal, artisanal green sea turtle fishery has uncovered a ... in what may have become an unsustainable take, according ... University of Florida. , During the research period, conservation ... killed between 1991 and 2011, with catch rates peaking ...
(Date:4/16/2014)... you cannot lift your upper eyelid. You walk through life with ... they are rolled down in the eye socket. Obviously, such a ... their head. In order to correct this condition, one would need ... the April 16 print issue of the journal Neuron , ...
Breaking Biology News(10 mins):Some immune cells defend only 1 organ 2Declining catch rates in Caribbean green turtle fishery may be result of overfishing 2Declining catch rates in Caribbean green turtle fishery may be result of overfishing 3Researchers track down cause of eye mobility disorder 2
... A deep ocean current with a volume equivalent to 40 ... near the Kerguelen plateau, in the Indian Ocean sector of ... paper published today in Nature Geoscience , the researchers ... surface as an important pathway in a global network ...
... National Oceanography Centre in Southampton, have today set sail from ... Ocean affected by ash from the Icelandic volcano eruption to ... of the ocean the productivity of microscopic plants, called phytoplankton, ... sequester carbon dioxide from the atmosphere, is limited by the ...
... Spanish . , Two new compact oakleaf ... by Agricultural Research Service (ARS) scientists. "Ruby Slippers" ... geneticist Sandy Reed with the U.S. National Arboretum,s Floral ... The arboretum is operated by ARS, the principal intramural ...
Cached Biology News:Massive Southern Ocean current discovered 2Scientists to measure impact of volcanic ash on ocean biology 2New hydrangea cultivars for landscape gardens 2
[14C]Polyethylene glycol 4000, 9.25 MBq, 250 uCi. Aqueous solution containing 3% ethanol, sterilized. 370-740 MBq/g, 10-20 mCi/g.1.85 MBq/ml, 50 uCi/ml. Category: Radiochemicals &Radiation Safety, ...
An instrument that delivers an accurate and uniform amount of light energy to cells to photoactivate csiRNA products....
... kit for all types of yeast two-hybrid studies, including ... Choice of two bait vectors for ... Triple reporter strain ... Complete set of controls: pLexA-p53, ...
interferon-related developmental regulator 2...
Biology Products: